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Abstract
This paper reviews functions of Amyloid-β (Aβ) in healthy individuals compared to the
consequences of aberrant Aβ in Alzheimer’s disease (AD). As extraneuronal Aβ accumulation
and plaque formation are characteristics of AD, it is reasonable to infer a pivotal role for Aβ in
AD pathogenesis. Establishing progress of the disease as well as the mechanism of
neurodegeneration from AD have proven difficult (Selkoe, 1994). This thesis provides evidence
suggesting the pathogenesis of AD is due to dysfunctional neuronal processes involving Aβ’s
synaptic malfunction, abnormal interaction with tau, and disruption of neuronal homeostasis.
Significant evidence demonstrates that AD symptoms are partially due to aberrant Aβ, and
further experimental research may focus on repairing or preventing the noxious effects of Aβ.

ALZHEIMER’S AND AMYLOID BETA

4

Alzheimer’s and Amyloid Beta: Amyloidogenicity and Tauopathy via Dyshomeostatic
Interactions of Amyloid Beta
Introduction to Alzheimer’s Disease
Background: Amyloid Beta and Alzheimer’s Disease
AD is the sixth leading cause of death in the United States, following accidents and
strokes. Compared to other top ten leading causes of death in the United States, methods of
preventing, curing, or slowing AD are exceptionally inefficient. In the United States alone, AD
kills more than 93,000 people each year, which is more than breast cancer and prostate cancer
combined. Additionally, there are over five million Alzheimer’s patients in the United States or
about one in ten people over the age of sixty-five (CDC, 2017). Furthermore, the incidence of
Alzheimer’s is increasing. From 1999 to 2014, deaths from Alzheimer’s have increased an
astounding fifty-five percent. Though the aging population is increasing, this alone cannot
account for the fifty-five percent increase in deaths from AD. By 2050, an estimated sixteen
million Americans will be diagnosed with Alzheimer’s (CDC, 2017). Research in preventing and
curing AD is some of the most vital research in the future of medicine. Currently, there are many
hypotheses which attempt to explain the pathogenesis of AD. One of the most convincing
hypotheses is the Amyloid-β hypothesis, which predicts that AD results from an accumulation of
Aβ protein in the interstitial matrix between the neurons of the brain (Qiu et al., 2015).
This thesis will review normal Aβ function and contrast it with the abnormal function and
accumulation of Aβ that has become a characteristic component of Alzheimer’s pathology.
Specifically, Aβ is known to result in synaptic interference, disruption of neuronal homeostasis,
and abnormal interaction with tau. These interactions initiate the formation of the amyloid
plaques and neurofibrillary tangles (NFT’s) characteristic of AD. Considering these major
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disruptions, this paper will review evidence that Aβ disruptions are closely associated with—and
are likely an underlying cause of— the physical symptoms of AD.
This paper proposes that the Amyloid-β plaques and NFTs present in the brains of
Alzheimer’s patients result from the many toxic effects of Aβ and its dysfunction. While it is
known that abnormal Aβ is present in amyloid plaques, the exact involvement of Aβ in the
mechanism of cell death has yet to be determined (Murphy and LeVine, 2010). Aβ exists in
multiple forms. Some forms have a propensity to polymerize and initiate plaque formation, but
the involvement of Aβ plaques in cell death is still under investigation. Consequently, the
mechanism of how specific isoforms of Aβ lead to cell death must be investigated. Specifically,
research will be reviewed to determine the extent of evidence supporting or contradicting the
involvement of Aβ in hallmark pathology of AD. Associations between Aβ, amyloid plaques,
NFTs, and cell death will be examined in the context of the chronology of AD pathophysiology.
Though this paper’s intentions are primarily to demonstrate that Aβ-induced malfunctions are
what eventually causes the physical symptoms of Alzheimer’s, the mechanism by which it does
so is also critical and will be given significant consideration.
The main objective of this thesis is to demonstrate the physical symptoms of AD are a
result of Aβ-mediated synaptic malfunction, improper interaction with tau, and disrupted
neuronal homeostasis. Additionally, this review will propose a method of how Aβ may lead to
the neurodegeneration that is caused by Alzheimer’s. This research holds important implications
for Alzheimer’s research, in that it seeks to clarify whether there is sufficient clinical and
mechanistic data to conclude that Aβ malfunctions induce the physical symptoms of
Alzheimer’s. Specifically, if Aβ-mediated cellular and synaptic disruptions can be demonstrated
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to be the primary link between the pathological and physical symptoms of Alzheimer’s, then
further research can focus on preventing and reversing these malfunctions. Historically, AD
research has focused primarily on Aβ induced malfunction, however, this research seeks to
present a more comprehensive representation of the disease and inspire novel research strategies.
Post-Translational Cleavage of the Amyloid Precursor Protein
Significant confusion has surrounded the research regarding Aβ and Amyloid precursor
protein (APP). This confusion is primarily due to the two main avenues in which APP is
processed. The differences between these two pathways are post-translational, they differ only in
the cleavage point on APP, and by which enzymes they are cleaved by. The two pathways have
been referred to as the non-amyloidogenic and the amyloidogenic pathway of APP processing. In
the non-amyloidogenic pathway, APP is cleaved by α-secretase to produce two protein
fragments: sAPPα and c83. sAPPα is proposed to have neuroprotective and neurotrophic
properties. C83 is further processed by γ-secretase to produce p3 and AICD (APP Intracellular
Domain). While no functions are currently known for p3, AICD may function as a transcription
factor (Multhaup et al., 2015).
In the amyloidogenic pathway, APP is processed by γ-secretase and β-secretase to
produce three peptide fragments: sAPPβ, AICD, and Aβ. Functions of sAPPα and sAPPβ can be
considered identical. The last fragment in amyloidogenic processing of APP is that of Aβ, the
namesake fragment of the amyloidogenic cleavage pathway and the main component in the
amyloid plaques characteristic of AD (Pearson and Peers, 2006). The term amyloid is a broad
term for an irregular aggregation of proteins. Aβ is thus named for its tendency to aggregate.
When discussing Aβ, it is vitally important to specify the type of Aβ. Aβ exists in two basic
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monomeric forms, Aβ1-40 and Aβ1-42; however, each of these monomers can also selfassemble into dimers, oligomers, and polymers (or fibrils) (Pearson and Peers, 2006). Unless
otherwise specified, the studies reviewed in this thesis regard Aβ1-42.
Aβ Roles in Physiology at Homeostasis
Despite the overwhelming research dedicated to determining the cytotoxic effects of Aβ,
many studies propose roles for Aβ or APP and its derivatives in normal physiology.
Furthermore, several studies demonstrate that certain species of Aβ are even critical for neuronal
survival. Multiple studies report that Aβ is found in the plasma and cerebrospinal fluid of nonAD individuals, indicating a possible homeostatic role for Aβ, or at least, as a byproduct of
normal physiological processes. Plausible functions of the distinct species of Aβ range from
immune defense via microbicidal effects, managing synaptic interactions and activity, acting as a
neurotrophic factor or an antioxidant, involvement in neuronal growth or lipid metabolism,
among other potential roles (Spitzer et al., 2016, Pearson and Peers, 2006, Cárdenas-Aguayo et
al., 2014, Zinser et al. 2007). APP has a potential role in cell adhesion, neuronal growth, and
formation of synapses (Cárdenas-Aguayo et al., 2014). Evidence of Aβ in normal brain
physiology suggests that Aβ’s presence alone does not induce the destructive physiological
malfunctions in AD.
Historical Aβ Pathophysiology
Plaque composition. Amyloid plaques, otherwise known as senile plaques, are one of
the most well- documented characteristics of the AD affected brain. Amyloid plaques are
composed primarily of the distinct species of Aβ (Pearson and Peers, 2006). Of the two forms,
Aβ1-42 has a higher affinity for aggregation, and is the main element of amyloid plaques.
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Though Aβ1-42 aggregates more readily, it is unclear if this equates to higher toxicity. It is also
uncertain whether amyloid plaque formation is a result of processes which drive the
pathophysiology of AD, or if the plaques themselves play a part in the pathophysiology of the
disease (Qiu et al., 2015). In addition to Aβ, there are over four-hundred fifty proteins that have
been found in amyloid plaques. These proteins are involved in cell adhesion, transport, cell
structure, inflammation, phosphorylation and dephosphorylation, metabolism, and protein
degradation (Liao et al., 2004). APP and tau filaments are also known to accumulate in these
plaques (Cras et al., 1991). This thesis, however, will focus on the primary elements that
compose amyloid plaques.
Species of amyloid beta and associated toxicity. Aβ1-40 and Aβ1-42 and their
monomers, dimers, and polymers have been indicated in the pathophysiology of AD.
Considerable AD research has focused on determining which form or forms of Aβ are the toxic
species. This research is often contradictory, making it difficult to determine which species are
likely to contribute to the physiological symptoms of AD. Historically, research has focused on
the polymeric forms of Aβ due to their prevalence in amyloid plaques. This thesis will review the
cytotoxicity of the various species due to recent discoveries and new insight pertaining to AD
pathophysiology.
Aβ1-42. Forms of Aβ1-42 have been classically considered the more neurotoxic species
of Aβ due to their increased tendency to aggregate (Qiu et al., 2015). Monomeric forms of Aβ142 are able to produce reactive oxygen species and decrease cell viability, but significantly less
than the oligomer and polymer forms of Aβ1-42. Aβ1-42 monomeric ROS production has been
reported to be about 2.5 times lower than ROS production due to Aβ1-42 oligomers and
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polymers. Additionally, the monomeric form of Aβ1-42 effects neuronal viability 10-40 times
less than its other forms (Giovanna et al., 2009). Interestingly, the Aβ1-42 monomer has not
classically been considered toxic on its own; only upon oligomerization and polymerization has
it been hypothesized that Aβ1-42 exhibits detrimental effects (Qiu et al., 2015). However, in
recent years new data has come to light that has made many researchers doubt the original
interpretation of the amyloid hypothesis, or that Aβ plaques created by polymerization initiate
neurodegeneration in AD.
Many studies that have examined the cytotoxicity of the different species of Aβ have
found that Aβ1-42 oligomers exert the greatest adverse effects on neurons (Sengupta et al.,
2016). Apart from monomeric forms, Aβ1-42 forms tetramers, pentamers, hexamers, and even
dodecamers prior to forming larger oligomers and fibrils (Qiu et al., 2015). Interestingly, toxicity
of oligomers has been reported to be inversely related to their size. As the size of an oligomer
increases, the less harmful it is to nearby cells (Sengupta et al., 2016). In general, Aβ1-42
oligomers have been the species indicated in Aβ ROS production and toxicity. Additionally,
Aβ1-42 oligomers are the only species of Aβ that exhibit the ability to form non-selective and
voltage-independent ion channels. These oligomeric Aβ1-42 species insert into membranes and
disrupt ion homeostasis. Calcium dysregulation has been especially noted as a cytotoxic
mechanism due to calcium’s role in many cell-signaling pathways (Bode et al. 2016).
Aβ1-42 fibrils and its aggregates have classically been considered to be involved in the
pathophysiology of AD, perhaps because they are highly present in one of the most distinctive
features in the AD brain, amyloid plaques. Aβ1-42 fibrils form more readily than Aβ1-40 fibrils,
but are less cytotoxic than other forms of Aβ1-42 and produce significantly less ROS, likely due
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to their inability to enter cells (Sengupta et al., 2016). Regardless, Aβ1-42 fibrils appear to be
more of a byproduct of neuronal dysfunction, rather than a primary factor in the induction of cell
death.
Aβ 1-40. Though Aβ1-40 appears to be less cytotoxic than Aβ1-42, many researchers
believe it is involved in the pathophysiology of AD, while others believe Aβ1-40 species are not
toxic at all. In the last twenty years, few articles have shown Aβ1-40 to have cytotoxic effects.
Before this time period, it was hypothesized that Aβ1-40 may form ion channels in neuronal
membranes; however, more recent research indicates that Aβ1-42 is the only form of Aβ able to
do so. While Aβ1-40 monomers are the most abundant isoform of Aβ in the human brain, it is
generally accepted that this is not a toxic species of Aβ (Bode et al. 2016). In fact, several studies
have shown that Aβ1-40 may have neuroprotective properties via antioxidation or inhibition of
lipid metabolism or aggregation of Aβ1-42 (Pearson and Peers, 2006, Cárdenas-Aguayo et al.,
2014, Qiu et al., 2015). Aβ1-40 tends to fluctuate between monomers, dimers, trimers, and
tetramers, but these do not easily polymerize. In vitro and in vivo models have successfully
polymerized Aβ1-40, but using much higher concentrations of Aβ1-40 than are present in an AD
brain. While Aβ1-40 fibrils have been reported to be cytotoxic, they are still significantly less
cytotoxic than Aβ1-42 oligomers or fibrils (Okada et al., 2007). In transgenic models of Aβ1-40
overexpression in mice, no amyloid plaques were found to be formed by Aβ1-40 (Qiu et al.,
2015). While Aβ1-40 should not be completely disregarded in the study of AD, evidence
suggests Aβ1-42 may play a more significant role in AD pathophysiology than Aβ1-40.
The Aβ1-42 : Aβ1-40 ratio. In recent years it has been proposed that the ratio of Aβ1-42
to Aβ1-40 is more important than individual levels of a single form of Aβ. In a typical non-
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diseased human brain, the ratio of Aβ1-42 to Aβ1-40 is about 1:9 (Pauwels et al., 2011).
However, in familial or early onset AD this ratio is elevated with mutations of the PS1 and PS2
genes (Sengupta et al., 2016). Nonetheless, only about 10% of AD cases are due to these
inheritable mutations. This ratio has also been shown to influence oligomer growth, binding to
neuronal membranes, synaptotoxicity, memory formation in animals, and neuronal viability
(Johnson et al., 2013). While current studies are examining the effects of lifestyle factors such as
diet and exercise on this ratio, results thus far have been inconclusive and further research is
warranted. Furthermore, while research has demonstrated that Aβ1-42 : Aβ1-40 induces
inflammation or oxidative stress, this relationship has only been demonstrated unidirectionally.
Further research is required to determine the factors which influence the Aβ1-42 : Aβ1-40 ratio.
Regardless, at physiological conditions, enough Aβ1-40 is present to inhibit Aβ1-42
polymerization, so with a decrease in the ratio of Aβ1-42 to Aβ1-40 the probability of forming
toxic Aβ1-42 oligomers and polymers decreases (Jan et al., 2008). Appropriately, as this ratio
increases, neurotoxicity increases and cell viability decreases (Kuperstein et al., 2010).
Research Review
Synaptic Interactions of Amyloid Beta
Considerable research has been directed toward investigating the activity of Aβ at synapses.
Several studies have demonstrated that certain forms of Aβ may play a normal role in
modulating synaptic activity. Other studies suggest that Aβ could have negative interactions at
synapses (Abramov et al., 2009, Pearson and Peers, 2006). Additionally, Aβ formation and
secretion are influenced by synaptic activity (Kamenetz et al., 2003). Interestingly, AD has even
been proposed to spread through the brain via synapses. Aβ is released at synapses and
subsequently affects postsynaptic neurons via alteration of receptors and intracellular ion
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concentrations, initiating intracellular processes which drive β-secretase cleavage of APP and,
thus, production of Aβ in the postsynaptic cell. Additionally, synaptic excitation increases APP
processing towards Aβ production. In AD, areas of increased neuronal activity correlate with
amyloid deposition (Pignataro and Middei, 2017). Regardless, accumulation of Aβ and synaptic
degeneration is a crucial step in neurodegeneration and neuronal death, thus, synaptic
interactions of Aβ are critical in the pathophysiology of the disease.
Aβ induced calcium dysregulation. There are numerous interactions of Aβ at the
synapse. A major synaptic disruption that occurs in AD is ion dysregulation. Particularly,
calcium dysregulation has been proposed to play a role in the pathophysiology of AD. Aβ has
been proposed to dysregulate calcium levels in a variety of ways.
One of the mechanisms by which Aβ may disrupt calcium concentrations is by directly
inserting into the membrane and forming ion channels. Aβ1-42 oligomers are the species
suspected of this channel-forming ability. Ion channels formed by Aβ1-42 oligomers disrupt ion
homeostasis across the neural membrane with adverse downstream effects. Specifically,
disruption of calcium homeostasis by Aβ1-42 oligomer ion channels is thought to contribute to
the physiological symptoms of AD. As Aβ1-42 ion channels create pores in the neural
membrane, both electrostatic pressure and the concentration gradient drive calcium ions into
neurons, creating an excess of intracellular calcium (Bode et al. 2016). Aβ1-42 also disrupts
other channels in the neuronal membrane such as voltage-gated calcium channels and L-type
calcium channels. Aβ1-42 binding to voltage-gated calcium channels activates the channel,
creating an abnormal influx of calcium into the cell. Aβ1-42 also directly increases the amount of
L-type calcium channels in neuronal membranes via association with the α1C subunit of the L-
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type calcium channel, increasing calcium influx into the cell. An increase in L-type calcium
channels is either due to an Aβ1-42 dependent increase of calcium channel trafficking to the
membrane, or Aβ1-42 inhibits removal of calcium channels from the membrane (D’Andrea,
2016). Additionally, Aβ1-42 binds to and inhibits the α7 nicotinic acetylcholine receptor, which
mediates release of acetylcholine and calcium influx. This may cause a compensatory increase in
other mediators of calcium, causing intracellular calcium levels to increase. Calcium homeostasis
and acetylcholine are both sensitive factors involved in memory and cognition, so disruptions in
these areas would impact memory and cognition (D’Andrea, 2016). In addition, Aβ1-42 induces
N-methyl-D-aspartate receptor (NMDAR) activation and subsequent calcium influx (West et al.,
2001). Certainly, there are a number of established mechanisms by which Aβ1-42 causes
calcium influx. The question is then: how does increased intracellular calcium cause
neurotoxicity and neurodegeneration? The broad answer to this question is by enabling or
inhibiting calcium-dependent intracellular pathways (D’Andrea, 2016). In the normal physiology
of a cell, calcium is highly involved in secondary messenger systems. In AD, however, many of
these networks are defective. cAMP response element-binding protein (CREB) signaling for
example, is disrupted in AD (D’Andrea, 2016). Increased intracellular calcium increases CREB
phosphorylation at Ser133, Ser142, and Ser143 via activation of kinases such as Calcium/CaMdependent kinase IV (CaMKIV) and MAPK. Increases in CREB phosphorylation leads to
upregulation of target genes which may then produce gene products which further drive disease
pathophysiology (Kornhauser et al., 2002). Many genes are regulated by CREB via
phosphorylation by calcium/calmodulin (CaM)- dependent protein kinases (Wang et al., 2014).
CREB-regulated genes are involved in intracellular events such as long-term potentiation,
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neuronal survival, circadian rhythms, exocytosis/endocytosis, and metabolism (Zhang et al.,
2005). CREB-regulated genes are known to partially mediate trophic factors as well as synaptic
plasticity (Hardingham et al., 2001). Calcium/CaM- dependent protein kinases have also been
known to activate some adenylyl cyclases, thus increasing cAMP levels. An increase in cAMP
increases CREB-dependent transcription (West et al., 2001). Thus, several mechanisms exist
which may up-regulate genes containing CRE’s. Interestingly, however, phosphorylated CREB
is decreased in AD, leading to a reduction in expression of CREB-regulated genes (Reese and
Taglialatela, 2011). This may lead to inhibition of CREB activation of pro-apoptotic processes,
leaving the cell unable to perform controlled cell death (Reddy and Beal, 2008).
Calcineurin (CaN) is also heavily influenced by a dysregulation of calcium homeostasis
in AD. Increases in intracellular calcium activate CaM, which then subsequently activates CaN
(D’Andrea, 2016). An increase in CaN has been proposed to cause an increase in long-term
depression and loss of memory (Berridge, 2013). CaN composes 1% of all proteins in neurons,
so any disruption in its expression can have severe results. CaN itself has several effects at the
synapse. CaN dephosphorylates voltage-dependent sodium channels, potassium channels, and Ltype calcium channels, so its activation can affect ion concentration and membrane polarization.
CaN is also heavily involved in synaptic release of neurotransmitters from the presynaptic
neuron. It has been proposed to dephosphorylate proteins crucial to the release of glutamate as
well as regulation of endocytosis. Thus, it decreases glutamate release and slows endocytosis.
CaN is also known to dephosphorylate NMDARs, closing the channels (Reese and Taglialatela,
2011). The NMDA receptor has been indicated as crucial to forming memories. Furthermore,
activation of CaN by CaM leads to phosphorylation of proteins resulting in synaptic loss of
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proteins, inhibition of neurotransmission, neuroinflammation, tau phosphorylation and even cell
death. In the AD brain, CaN has been shown to be overexpressed and CREB phosphorylation is
reduced in the hippocampus. It is possible this is due to increased CaN, but other mechanisms are
likely involved as well. CREB dephosphorylation is associated with loss of synaptic proteins
(Reese and Taglialatela, 2011). CaN upregulation forms a negative feedback loop via
dephosphorylation of nuclear activator of T-cells (NFAT) and a subsequent increase in RCAN1,
a regulator of CaN activity. Since CaN is a regulator of CREB, this may lead to excessive
transcription of CREB and subsequent cell death (Hoeffer et al., 2007). Furthermore, NFAT
dephosphorylation is associated with neuroinflammation (Reese and Taglialatela, 2011).
Additionally, regulator of calcineurin 1 (RCAN1) inhibition of CaN and activation of glycogen
synthase kinase-3 β (GSK3β) decreases dephosphorylation in tau and hyperphosphorylates tau,
respectively, leading to further toxicity (Lloret et al., 2011). CaN also dephosphorylates the
Bcl2-associated death promoter and pPP1, which are involved in inducing apoptosis and in
neurotransmission, respectively (Reese and Taglialatela, 2011).
Another method by which calcium dysregulation may disrupt the synapse is by
interfering with synaptic mitochondria. Damaged mitochondria produce free radicals which
promote β-secretase cleavage of APP. This produces Aβ oligomers which further impair synaptic
mitochondria function. Aβ oligomers may then be exported outside the cell where they
polymerize and aggregate to form amyloid plaques. Meanwhile, damaged presynaptic
mitochondria produce less ATP and are unable to sustain the metabolic demands of the
presynaptic neuron. These events are hypothesized to interfere with presynaptic exocytosis and
impair neurotransmission via glutamate and NMDARs (Avila, 2011).
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Excessive intracellular calcium has also been demonstrated to induce apoptosis as well as
creation of free radicals and reactive oxygen species. Mitochondria and the endoplasmic
reticulum are both highly involved in these processes (LaFerla, 2002). Though excessive
intracellular calcium may be caused by synaptic disruptions, the effects of intracellular calcium
reach far beyond the synapse. These non-synaptic disruptions will be discussed later in this
thesis.
Cholinergic disruptions of amyloid beta. Expression of muscarinic cholinergic
receptors are also disrupted in AD. M1-M4 muscarinic receptors are expressed at lower levels in
the hippocampi of AD patients compared to age-matched controls. Lower levels of M4 receptors
have been particularly well characterized in AD. Further studies have demonstrated a decrease in
M2 receptors compared to M1 and M3 receptors. M2 receptors have been proposed to inhibit
expression of β-secretase, leading to a decrease in Aβ. Since these are under-expressed in the AD
brain, Aβ is more likely to accumulate. Stimulation of M1 and M3 receptors increases γsecretase cleavage of APP, reducing levels of harmful Aβ. M1 may even reduce the toxicity of
Aβ through a GSK3-regulated pathway (El-Hassar et al., 2011). Regardless, there is certainly
evidence for disruption of acetylcholine in AD synapses. Acetylcholine binds to postsynaptic
muscarinic receptors, which are coupled to intracellular G-proteins. G-protein activation initiates
several intracellular signaling pathways. While acetylcholine disruptions may play a part in the
pathophysiology of AD, glutamatergic disruptions have been better characterized in the disease.
Glutamatergic disruptions of amyloid beta. Aβ oligomers directly disrupt a variety of
glutamatergic postsynaptic proteins such as NMDARs and metabotropic glutamate receptors
(Ovsepian et al., 2018). These receptors are expressed at lower levels in AD patients.
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Furthermore, research has demonstrated that exogenous Aβ treatment increases endocytosis of
NMDARs in mouse and human cortical neurons. This may be a response to the increase in
intracellular calcium caused by Aβ-dependent NMDAR activation (West et al., 2001).
Regardless, extracellular Aβ oligomers have been demonstrated to directly activate NMDARs on
post-synaptic neurons. Aβ oligomer activation of NMDARs induces further calcium influx into
neurons and increases the probability of calcium induced neural toxicity as well as increases the
probability of post synaptic neural firing (Texidó et al., 2011). Interestingly, prolonged NMDAR
activation by Aβ results in high intracellular calcium, leading to an increase in vesicular merging
with the neuronal membrane, and endocytotic transport of APP to late endosomes. APP is then
cleaved by β-secretase to form the β-CTF. When this is further cleaved by γ-secretase it forms
toxic Aβ peptides, adding to the neurotoxic load (D’Andrea, 2016).
Many studies have characterized the disruption of the glutamate system in AD. Aβ
oligomers increase extracellular glutamate stores due to an induction of glutamate release and
reduction of synaptic glutamate reuptake. Increased extracellular glutamate increases the
likelihood that a neuron will fire. This build-up of synaptic glutamate may cause glutamateinduced excitotoxicity (Pignataro and Middei, 2017) However, these effects are likely after
neurons lose sensitivity to the depressive effects of Aβ, as Aβ is well known to depress synaptic
activity at physiological levels (Pearson and Peers, 2006). While the toxic effects of the NMDA
glutamate receptor have already been discussed in detail, mechanisms of metabotropic glutamate
disruption in the AD brain must also be discussed. Significantly, metabotropic glutamate
receptor (mGluR) signaling is highly dependent on both intracellular and extracellular calcium
levels in neurons. Synaptic calcium reduction leads to a significant reduction in postsynaptic
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mGluR activity; thus an increase in intracellular calcium may lead to downstream inhibition of
mGluR activity and disruption of glutamate mediated intracellular cascades (Revett et al., 2013).
Group 1 mGluRs have been shown to increase intracellular calcium via IP3 and ryanodine
triggered calcium release from the ER, so a buildup of synaptic glutamate induced by Aβ likely
adds to calcium dysregulation and cellular dysfunction (Schapiro et al., 2010). AMPA receptors,
a type of ionotropic glutamate receptor, are also disrupted in AD brains. Aβ has been shown to
increase endocytosis of these receptors, thus decreasing their effect at synapses. In fact, in rat
models of AD, AMPAR decrease at synapses has been demonstrated to facilitate dendritic spine
loss and long-term depression after Aβ treatment. Associated endocytosis of GluRs has also been
shown to reduce synaptic AMPAR levels. Furthermore, Aβ interferes with calcium/CaM which
is involved in AMPAR delivery to synapse. AMPARs are permeable to calcium, sodium, and
potassium, so AMPAR disruption leads to neuronal depolarization. Thus, Aβ induces long-term
depression in part by dysregulation of AMPARs (Revett et al., 2013).
Vesicular disruptions of amyloid beta. Aβ oligomers contribute negative effects on
vesicle trafficking at the presynaptic side. Endocytosis is slowed, and synaptic vesicle recycling
is impaired (Park et al., 2013). Aβ has been shown to impair Soluble NSF Attachment Protein
Receptor or SNARE-dependent exocytosis via blockage of zippering (Ovsepian et al., 2018). Aβ
has also been shown to decrease expression of dynamin 1 and synaptophysin, two proteins
heavily involved in endocytosis, likely leading to a decrease in the formation of endocytic
vesicles (Ovsepian et al., 2018). Decreased endocytosis and exocytosis can cause several
deleterious effects in neurons from disruption of neurotransmitter and membrane protein levels
to intracellular accumulation of toxins (Ovsepian et al., 2018).
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Amyloid Beta Interactions with Tau/NFT’s
The other major hallmark of Alzheimer’s disease is that of intracellular NFTs. These
NFTs are composed primarily of the hyperphosphorylated form of tau protein, a microtubuleassociated protein (MAP). While normally positioned in axons, in AD pathology, tau is localized
to dendrites (Murphy and LeVine, 2010, Su, et al., 1997). Phosphorylated tau has a significantly
reduced ability to bind to microtubules and has a high affinity to polymerize with other tau
molecules. Tau molecules first associate to form straight filaments and eventually these straight
filaments join to form paired helical filaments (Revett et al., 2013). This review will center
primarily on the relationship of Aβ and tau, with a focus specifically on mechanisms by which
Aβ may contribute to tau pathology and NFT formation. Many studies have characterized a
decrease in CSF Aβ1-42 prior to increases in CSF tau and phosphorylated tau (Silverman et al.,
1997). In accordance with this, PET brain imaging studies have revealed that clinically
significant amyloid plaques form prior to cytotoxic NFTs, although NFTs are seen prior to
overall amyloid plaque accumulation. This seems to suggest that Aβ oligomers induce initial
formation of a small portion of NFTs, which in turn add to disease pathophysiology along with
accumulation of extracellular Aβ. Coupled together, these elements induce extracellular amyloid
deposits and subsequent formation of the majority of NFTs. Thus, this review proposes that
extracellular amyloid disruptions precede significantly toxic intracellular tau pathology in AD
(Blurton-Jones and LaFerla, 2006).
One of the main methods by which Aβ drives neurofibrillary pathology is by indirect
phosphorylation of tau. Several proteins are disrupted by Aβ, with downstream phosphorylation
of tau. For example, in rat models of AD, extracellular Aβ incites an increase in active and
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phosphorylated ERK1 and ERK2 and their activity in hippocampi. These kinases are involved in
several important neural functions such as modulation of synaptic plasticity, apoptosis, and
neuroinflammation. Phosphorylated ERK1 and ERK2 induce hyperphosphorylation of tau. This
occurs prior to amyloid plaque formation, suggesting soluble oligomers such as Aβ1-40 and
Aβ1-42 are likely to play a role in disruption of ERK1 and ERK2 signaling and subsequent
initiation of tau pathology (D’Andrea, 2016).
Another mechanism by which Aβ drives tau pathology is by promoting its aggregation.
In a mutant mouse model, early accumulation of Aβ correlated with tau redistribution and tau
hyperphosphorylation. Aβ and tau appear to first colocalize in dendrites and eventually localize
around neuronal projections around amyloid plaques (D’Andrea, 2016). When this occurs, tau is
phosphorylated by tau protein kinase II (TPK II). TPK II phosphorylation of tau is dependent
upon Aβ concentration. Thus, not only does Aβ induce tau aggregation, but also
hyperphosphorylation as well (D’Andrea, 2016).
Some mechanisms of tau phosphorylation depend upon Aβ’s ability to disrupt calcium
homeostasis in neurons. For example, Aβ’s ability to bind to the α7 receptor may also play a role
in tau pathology as Aβ binding results in hyperphosphorylation of tau. Several studies have
documented an interaction between the α7 receptor and NMDARs. α7 stimulation in glial cells
upregulates GLAST, a glutamate transporter. This process is mediated by fibroblast growth
factor and IP3-calcium/CaMKII pathways. Thus, stimulation of α7 nicotinic cholinergic
receptors may lead to neuroprotective uptake and clearance of glutamate from the synapse.
Excessive glutamate uptake in microglia may cause compensatory mechanisms to overproduce
glutamate, hence the extracellular glutamate build-up in Alzheimer’s disease (Akaike et al.,
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2018). Excessive glutamate may then disrupt calcium homeostasis and lead to downstream
phosphorylation of tau. mGluR2 has also been found in higher concentrations in the
hippocampi of patients with Alzheimer’s disease and are associated with an increase in
phosphorylated tau. Likely, overexpression of mGluR2 in AD hippocampi increases
intracellular calcium levels, initiating downstream activation of tau kinases and subsequent
phosphorylation of tau (Revett et al., 2013).
Yet another protein that is disrupted by Aβ in Alzheimer’s disease is Regulator of
Calcineurin-1, also known as RCAN1. RCAN1 increases when cells are experiencing oxidative
stress. Many forms of Aβ are known to induce oxidative stress and formation of reactive oxygen
species (ROS), thus Aβ has significant potential to disrupt expression of RCAN1. Oxidative
induction of RCAN1 overexpression has two potential consequences, inhibition of CaN leading
to a decrease in dephosphorylation of tau, and upregulation of GSK3β and subsequent
hyperphosphorylation of tau. These actions coupled together represent a significant mechanism
by which tau may become hyperphosphorylated (Lloret et al., 2011).
GSK3β plays an additional role in tau pathology and NFT formation. As explained
previously in this review, Aβ isoforms have been well characterized to increase intracellular
calcium concentrations. This increase occurs via direct stimulation of NMDARs, calcium
channels, or the ability of Aβ1-42 oligomers to form ion channels directly in the neuronal
membrane. An increase in calcium induces an increase in CaN/PP2B, which in turn induces an
increase in GSK3β activity and subsequent phosphorylation of tau and NFT pathology.
Additionally, GSK3β expression is elevated in multiple models of Aβ initiated tau pathology,
reinforcing the concept of Aβ/GSK3β induced tau pathology. In these models, inhibition of
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GSK3β decreases tau hyperphosphorylation (D’Andrea, 2016). Interestingly, Aβ’s ability to
decrease NMDAR dependent LTP has also been linked to GSK3β tau pathology (D’Andrea,
2016).
As many proteins are regulated by CaN, CaN clearly plays an important role in AD
pathophysiology. Several studies have demonstrated that neurons near amyloid plaques as well
as neurons with NFT’s demonstrate a strong reaction when probed with CaN antibodies. This
supports the hypothesis that CaN leads to downstream phosphorylation and
hyperphosphorylation of tau. In accordance with this, the CaN activator calmodulin (CaM) is
also over-expressed in the AD brain. This explains the imbalance of CaN kinase and phosphatase
activity, as excess CaM over-activates CaN, tipping the balance in the favor of CaN activation.
Interestingly, CaN has been proposed to interact with tau under normal circumstances, however,
when calcium concentrations rise, CaM is activated and subsequently binds to CaN. This
disrupts the interaction between CaN and tau and CaN is unable to dephosphorylate tau. Thus,
excessive calcium leads to overactivation of CaN, and a subsequent decrease in tau
dephosphorylation (Reese and Taglialatela, 2011).
Several additional kinases have also been found to be activated by Aβ1-40 and Aβ1-42.
These kinases then phosphorylate tau directly or lead to downstream phosphorylation of tau.
Other kinases which effect phosphorylation of tau include Fyn kinase, protein kinase c, calpain
(p35 and p25) and cyclin dependent kinase (Revett et al., 2013, LaFerla, 2002). While these
kinases may increase phosphorylation of tau, review of each kinase that does so is beyond the
scope of this thesis.
Evidence suggests that tau phosphorylation occurs prior to neuronal loss. It is likely that
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phosphorylation of tau and aggregation of Aβ are related and dynamic processes which are
significantly intertwined. Phosphorylation of tau causes neuronal death via destroying
microtubule function, thus, impairing axonal and vesicular transport and causing irregular
neuronal morphology. Inhibition of this process appears to prevent a portion of Aβ cytotoxicity.
Inhibition is achieved via interrupting tau kinase function. This has been shown to increase cell
viability. Furthermore, tau knockout animal models have shown to produce Aβ cytotoxicity
resistant mice (Revett et al., 2013).
Another mechanism by which Aβ may facilitate tau hyperphosphorylation is via
activation and increased expression of stress induced proteins. One such protein is the
mammalian target of Rapamycin, or mTor. mTor is an important protein involved in maintaining
oxygen, metabolic rate, and nutrient levels (Tokunaga et al., 2004). mTor is regulated by nutrient
and growth factor levels, as well as cellular stress. Though Aβ has been indicated in disruption of
growth factors and nutrient levels, significant research has demonstrated its ability to distress
cells. Particularly, Aβ has been shown to regulate ERK1 and ERK2 levels, which are also known
to activate mTor. Furthermore, mTor is inhibited by GSK3β, which is also disrupted by Aβ.
Several studies have demonstrated mTor activity disrupts several kinases resulting in
downstream phosphorylation of tau and even increases synthesis of tau itself (Tang et al., 2013).
Together, these results indicate that cellular stress induced by Aβ may induce mTor
overexpression and subsequently, tau pathology.
An abundance of research illustrates the interplay of Aβ, calcium dysregulation, and tau
disruption. In AD, microtubules are severely disrupted, and phosphorylation of tau has been
shown to have many negative downstream effects. Primarily, phosphorylated tau is believed to
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interact with unphosphorylated tau decreasing tubulin formation of microtubules. Phosphorylated
tau itself also does not bind microtubules, decreasing the amount of viable tau present in the cell.
On the other hand, dephosphorylation of tau has been shown to rescue functionality of tau in
vitro. Regardless, phospho-tau regulated disruption of microtubule assembly has been proposed
to disrupt axonal transport and possibly induce retrograde neuronal degeneration (Alonso et al.,
1994). Furthermore, tau paired helical filaments have been shown to inhibit neuronal
proteasomes, causing a further increase in toxic protein accumulation. Tau paired helical
filaments and subsequent NFT formation do in fact correlate with the severity of disease (Keck
et al., 2003). Finally, phosphorylation of tau has been shown to increase the detrimental
mitochondrial effects Aβ has in neurons (Quintanilla et al., 2014). As a result of this mass of
research on the role of tau in AD, dephosphorylation of tau is currently a major therapeutic aim
in AD.
Additional Homeostatic Disruptions of Amyloid Beta
Increase in intracellular calcium: non-synaptic effects. Intracellular calcium
accumulation leads to neurotoxicity through a variety of non-synaptic pathways. These include
ER disruptions, mitochondrial disruptions, and ROS production. In fact, when intracellular
calcium is artificially increased in cultured neurons, Aβ accumulates, tau becomes
hyperphosphorylated, and cells eventually die. Likely, intracellular calcium levels play a key part
in the neurodegeneration seen in AD. Furthermore, many of the genes affected in familial AD
are related to calcium signaling (LaFerla, 2002).
Additional mechanisms of Aβ toxicity involve neural ER and mitochondria. While these
organelles have very distinct functions within the cell, they each play a role in the regulation of
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intracellular calcium. In AD, the ER is heavily impaired by Aβ. In several in vivo studies, Aβ
stimulates IP3 and Ryanodine receptors in the ER, causing a significant efflux of calcium from
the ER. This depletion of ER calcium stores in part induces the unfolded protein response, which
will initiate apoptosis if chronically activated. ER stress may even further increase APP cleavage
by β-secretase inducing further Aβ production. Nonetheless, while mitochondria are often near
the ER, mitochondria take up extracellular calcium (Li et al., 2015). Increases in mitochondrial
calcium disrupt mitochondrial membrane potential and function. Severe disruption of the
mitochondrial membrane potential induces opening of the mitochondrial transition pore, which
releases ROS and proapoptotic substances, such as apoptosis inducing factor and cytochrome c
into the cell (Redza-Dutordoir and Averill-Bates, 2016). Disruption of mitochondrial membrane
potential disrupts the electron transport chain, and thus, ATP production decreases. Aβ has also
been found to directly disrupt mitochondrial protein transport. Specifically, Aβ treatment is
associated with a decrease in complex IV in the mitochondrial membrane, decreasing
mitochondrial ability to meet the metabolic demands of the neuron (Chen and Zhong, 2014).
This disruption is also associated with an increase in ROS, particularly, production of the
superoxide ion (Ferreiro et al., 2008). ROS damages mtDNA further compounding the effect of
mitochondrial membrane potential disruption (Redza-Dutordoir and Averill-Bates, 2016).
Aβ may also disrupt the balance of mitochondrial fusion and fission. In mouse models,
mice producing high levels of Aβ were found to have lower mitochondrial ATP production, an
increased rate of fission and associated proteins, and a decrease in fusion and associated proteins.
This creates a deficit in axonal and synaptic mitochondria leaving these areas vulnerable to
metabolic deficiency. Transgenic mice overexpressing Aβ not only demonstrated a fission and
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fusion imbalance, but also increases in ROS production and associated changes in oxidative
markers such as superoxide dismutase and 4-hydroxynonenal. Interestingly, a decrease in
mitochondrial proteins appears prior to mitochondrial membrane failure and oxidative stress.
Oxidative stress further exacerbates mitochondrial disfunction and feeds back to continue βsecretase cleavage and Aβ production. Mitochondrial dysfunction and Aβ toxicity are thus
closely associated. In Aβ transgenic mice, mitochondrial dysfunction and Aβ deposition increase
as the mice age. Furthermore, ROS facilitates tau hyperphosphorylation, increasing tau
pathology (Pagani and Eckert, 2011). In addition to mitochondrial ROS production, metal
accumulation and inflammation also contribute to neuronal oxidative stress. Aβ binds directly to
copper and iron, creating an accumulation of metal and producing hydrogen peroxide, further
promoting oxidative stress (Chen and Zhong, 2014). Furthermore, activated microglia and
astrocytes continually produce ROS as cellular byproducts (D’Andrea, 2016). Extracellular
oxidative stress can also induce cell death via induction of transmembrane cell death receptors
such as TNF receptor 1, TRAIL receptor 1 and 2, and the Fas receptor (Redza-Dutordoir and
Averill-Bates, 2016). Regardless of the source of ROS, oxidative stress disrupts mitochondrial
and cell function propelling the cell further toward death.
Amyloid disruptions of the ubiquitin-proteasome system. Apart from the detrimental
effects of intracellular calcium disruption, another mechanism through which Aβ may disrupt
neuronal homeostasis is via disruption of the Ubiquitin proteasome system. HIP-2, otherwise
known as UBE2K, is an ubiquitin conjugating enzyme which is suspected to contribute to Aβ
disruption of the ubiquitin proteasome system. In both in vivo and in vitro studies, Aβ1-42
treatment induced a significant overexpression of HIP-2/UBE2K in neurons. HIP-2/UBE2K’s
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activity is required for Aβ1-42 induced inhibition of the ubiquitin proteasome system and
subsequent neurotoxicity. Aβ1-42 has been proposed to inhibit proteasomal degradation of
aberrant protein leading to a buildup of dysfunctional protein in affected cells. Protein
aggregation induces the apoptotic marker apoptosis signal regulating kinase 1 and the c-Jun-Nterminal kinase, increasing the likelihood of neural apoptosis. Additionally, UBB+1, a
dysfunctional form of ubiquitin, has been found to associate with UBE2K and collect nearby.
UBB+1 has been proposed to inhibit the proteasome by binding dysfunctional proteins prior to
ubiquitin, and disabling the proteasome from removing the polyubiquitin chain and degrading
the protein, leading to accumulation of dysfunctional protein and subsequent cytotoxicity (Song
et al., 2003). Furthermore, HIP-2/UBE2K inhibition of the proteasome has been shown to
activate Caspase-12 in mice both by increasing levels of Caspase-12 mRNA and more indirectly
via inhibition of proteolysis of Caspase-12 and activation of Caspase-12 via endoplasmic stress
induced by proteasomal inhibition. Though the human homolog of Caspase-12 does not currently
have any known functions, other caspases may have similar defects when activated by Aβ in
humans (Song et al., 2008).
Aβ and neuroinflammation in AD. After review of several mechanisms by which Aβ
disrupts neuronal homeostasis, a crucial final consideration is the efficiency of the neural defense
mechanism against the extracellular perturbations which Aβ plaques present. In an attempt to
reduce these effects, neuroinflammation, or gliosis is initiated. In gliosis, microglia and
astrocytes function to eliminate extracellular depositions of debris. In this process, microglia and
astrocytes accumulate around debris to form glial scars. In AD, gliosis occurs in areas adjacent to
amyloid plaques. Glial cells then release proinflammatory cytokines (such as tumor necrosis
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factor-α, interferon-γ, and interlukin-1) and oxidants (superoxide and nitric oxide) which further
induce neural death. As neural inflammation and related cell death are secondary outcomes of
Aβ plaques, inhibition of inflammation alone does not stop the neurodegenerative effects of Aβ.
In mice models of AD, however, inhibition of neuroinflammation with non-steroidal antiinflammation drugs (NSAIDs) has been shown to inhibit plaque formation, decrease AD-like
symptoms and Aβ concentrations. Furthermore, patients with a history of NSAID use
demonstrate a significant decrease in microglia. This evidence suggests that inhibition of
inflammation may decrease secondary neural death and thus slow neurodegeneration in AD.
Though Aβ does provoke neuroinflammation, it is a secondary event in the pathogenesis of AD,
and it only exacerbates neural cell death. Furthermore, when neurons undergo apoptosis or lyse
due to intracellular Aβ accumulation further neuroinflammation is triggered, creating a cycle of
positive feedback in which inflammation initiates neural death which provokes further
inflammation and so on. Additionally, some studies report that proinflammatory cytokines can
increase expression of β-secretase, increasing Aβ formation and hyperphosphorylation of tau,
pushing cells further along in the pathophysiology of AD (D’Andrea, 2016).
Conclusions
Alzheimer’s disease is a physiologically devastating disease. While there are many
hypotheses of the pathophysiology of the disease, the hypothesis that has come closest to
explaining the research is the Amyloid-β hypothesis. This hypothesis states that extracellular Aβ
accumulation in the form of extracellular plaques initiate the pathophysiology of the disease.
While the evidence no longer appears to support this exact hypothesis, the contents of this thesis
have demonstrated that a similar mechanism likely initiates the pathophysiology of Alzheimer’s
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disease. While amyloid plaques have been shown to disrupt neuronal function, they do not
appear until late in the stages of Alzheimer’s disease. The research conducted in this study
suggests that the cytotoxic Aβ1-42 initiates a cascade of synaptic and intracellular events leading
to downstream neuronal death and neurodegeneration.
Synaptic Interactions of Amyloid Beta
The synaptic interactions of Aβ1-42 represent some of the most devastating effects of
amyloid in AD. Aβ1-42 oligomers have been shown to disrupt calcium homeostasis via a variety
of pathways. Prolonged increases in intracellular calcium wreaks havoc at the synapse, leading to
downstream genomic and neurotransmitter effects, phosphorylation of tau, creation of reactive
oxygen species, and further proliferation of Aβ1-42 in neurons. Cholinergic, glutamatergic, and
vesicular effects further amplify the effects of Aβ1-42. Combined, these downstream effects all
contribute to a mechanism of Aβ1-42 induced neuronal cell death.
Amyloid Beta Interactions with Tau/NFT’s
Aβ1-42 interacts indirectly with tau via a variety of pathways. Aβ1-42 effects
phosphatases and kinases and intracellular calcium with consequent hyperphosphorylation of tau.
While phosphorylation of tau disables its incorporation into microtubules, phosphorylated tau
also associates with non-phosphorylated tau, further decreasing the pool of tau available for
incorporation into functional microtubules. These effects interfere with axonal transport and
induce toxic accumulation of proteins and even increases the detrimental effects of Aβ. This
thesis suggests that AD is not a disease simply resulting from amyloid disruptions, but also, Aβ’s
antagonism of and synergy with the detrimental effects of phosphorylated tau.
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Other Homeostatic Disruptions of Amyloid Beta
Apart from the various effects of Aβ1-42 at the synapse and its interactions with tau,
Aβ1-42 has many additional effects which contribute to neuronal death. While synaptic effects
play a large role in neuronal death, Aβ1-42 initiates significant intracellular effects as well.
Intracellular calcium dysregulation depolarizes mitochondria and induces ER and mitochondrial
dysfunction, ROS production, and inflammation. Additionally, Aβ1-42 disrupts the ubiquitinproteasome system, causing aberrant protein accumulation and additional cytotoxicity. Oxidative
stress and ubiquitin-proteasome disruptions further impair the normal functioning of neurons,
adding to the catastrophic interactions of Aβ1-42 at the synapse and with tau.
While the classical amyloid hypothesis does not explain the current research on the
physiology of AD, the hypothesis should not be completely discarded. According to the classical
amyloid hypothesis, amyloid plaques composed of aggregations of Aβ induce the
pathophysiology of AD. As research on AD has progressed, amyloid plaques have come to be
seen as downstream effects of disruptions of normal cell biology. This thesis has demonstrated
that cellular disruptions of Aβ precede the formation of both amyloid plaques and NFTs. This
thesis also provides evidence that Aβ disruptions induces extracellular and intracellular
consequences which induce the pathophysiology of AD. There are several approaches which
may prove to be successful in mediating the adverse effects of Aβ in the AD brain. Prevention of
AD should be the primary focus of AD research. This begins with APP processing. Stimulation
of α-secretase cleavage of APP and inhibition of β-secretase cleavage prior to or early in disease
pathology would likely prevent the physiological abnormalities of AD. Aβ clearance or
degradation in early stages of AD would also cease progression of the disease. As a majority of
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AD research focuses on reversing the neurodegeneration characteristic of the disease,
experimental research must be redirected to address preventing the disease entirely or stopping
the disease in its early stages. While reversal of neurodegeneration, induction of neurogenesis,
reformation of neural pathways, and complete cognitive restoration are all ideal and noble
endeavors, it may prove beneficial for AD research to explore alternative approaches to defeating
the neurological atrocity that is Alzheimer’s disease.
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